Study: Covidien's stroke device beats standard therapy

In an independent study by the University of Edinburgh, Covidien's ($COV) Kendall SCD system decreased deep vein thrombosis by 29.9% in immobile stroke patients and reduced mortality risk by 14% compared to routine therapy. Kendall SCD is currently recommended only for stroke sufferers who can't tolerate blood-thinning injections, but the investigators say the device could save as many as 10,000 lives each year with wider use. More

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.